Search results for "030211 gastroenterology & hepatology"

showing 10 items of 1275 documents

Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort

2016

Background: Natural history of primary biliary cirrhosis (PBC) is partially characterized in patients from the Mediterranean area whose genetic background differs from that of Northern Europeans. Objectives: We aimed to describe genetic susceptibility and clinical course of PBC in patients from Southern Italy. Methods: Socio-demographic, clinical, biochemical and histological data at diagnosis as well as disease progression of 81 PBC consecutive patients were collected. All subjects were treated with Ursodeoxycholic acid at a dose of 15 mg/kg. HLA class II DRB1 alleles were compared with those of 237 healthy control subjects. IL28B genotyping for IL28B rs12979860 C/T and rs80899917 G/T was …

0301 basic medicinemedicine.medical_specialtyPrimary biliary cirrhosimedicine.medical_treatmentLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicinePrimary biliary cirrhosisGeneticInternal medicineGenotypemedicineGenetic predispositionProspective cohort studySettore MED/04 - Patologia GeneraleAutoimmune diseaseSettore MED/12 - GastroenterologiaPrimary Biliary CirrhosisHepatologybusiness.industrymedicine.diseaseKowsarTransplantation030104 developmental biologyInfectious DiseasesGenetic; Natural history; Primary biliary cirrhosis; Hepatology; Infectious Diseases030211 gastroenterology & hepatologybusinessResearch ArticleNatural HistoryHepatitis Monthly
researchProduct

Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis

2016

BACKGROUND Fibrosis as a common problem in patients with Crohn's disease is a result of an imbalance toward excessive tissue repair. At present, there is no specific treatment option. Pirfenidone is approved for the treatment of idiopathic pulmonary fibrosis with both antifibrotic and anti-inflammatory effects. We subsequently investigated the impact of pirfenidone treatment on development of fibrosis in a new mouse model of intestinal fibrosis. METHODS Small bowel resections from donor mice were transplanted subcutaneously into the neck of recipients. Animals received either pirfenidone (100 mg/kg, three times daily, orally) or vehicle. RESULTS After administration of pirfenidone, a signif…

0301 basic medicinemedicine.medical_specialtyPyridonesBlotting Western610 Medicine & healthGastroenterologyImmunoenzyme TechniquesMice03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineTransforming Growth Factor betaFibrosis10049 Institute of Pathology and Molecular PathologyInternal medicinemedicineAnimalsImmunology and Allergy2715 GastroenterologyCell ProliferationMice Inbred BALB CbiologyCell growthbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyPirfenidoneTransforming growth factor betamedicine.diseaseFibrosisMice Inbred C57BLTransplantationBlotDisease Models AnimalIntestinal Diseases10219 Clinic for Gastroenterology and Hepatology030104 developmental biology2723 Immunology and Allergybiology.proteinFemale030211 gastroenterology & hepatologyCollagen10069 Clinic of Cranio-Maxillofacial SurgerybusinessAfter treatmentmedicine.drugInflammatory Bowel Diseases
researchProduct

The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update

2017

Gluten-related disorders have recently been reclassified with an emerging scientific literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E (non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms. This review article will provide clinicians with an update that directly impacts on the management of a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion.

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaGlutensamylase-trypsin inhibitors (ATIs)Gluten sensitivitylcsh:TX341-641Non-Celiac Gluten SensitivityReviewWheat HypersensitivityGastroenterologyIrritable Bowel Syndrome03 medical and health sciencesDiet Gluten-Free0302 clinical medicineMalabsorption Syndromesgluten-free dietMedizinische FakultätInternal medicineMedicineHumansddc:610Irritable bowel syndromeImmune mechanismsRandomized Controlled Trials as Topicgluten-related disorder030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industrygluten sensitivitynutritional and metabolic diseasesGluten-related disordersWheat-Sensitive Irritable Bowel Syndromemedicine.diseaseMalabsorption Syndromedigestive system diseasesNon-Celiac Gluten Sensitivity; Wheat-Sensitive Irritable Bowel SyndromeReview articlewheat allergy030211 gastroenterology & hepatologybusinessNon-celiac gluten sensitivitygluten-related disorderslcsh:Nutrition. Foods and food supplyWheat allergyGlutenceliac diseaseFood ScienceHuman
researchProduct

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nona…

2018

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B (PPP1R3B), which is involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver disease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carcinoma in a cross-sectional Italian cohort (n = 132 cases), and on liver disease at the population level in the …

0301 basic medicinemedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAPopulation03 medical and health sciencesLiver disease0302 clinical medicineLipid oxidationFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineeducationNASH NAFLDeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryOriginal ArticlesHepatologymedicine.diseasen/a030104 developmental biologyEndocrinologyLiver biopsy030211 gastroenterology & hepatologyOriginal ArticleSteatosisbusiness
researchProduct

P747 Predictors of thiopurine treatment failure in ulcerative colitis

2018

0301 basic medicinemedicine.medical_specialtyThiopurine methyltransferasebiologybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisGastroenterologyTreatment failure03 medical and health sciences030104 developmental biology0302 clinical medicineInternal medicinebiology.proteinmedicine030211 gastroenterology & hepatologybusinessJournal of Crohn's and Colitis
researchProduct

Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia

2019

Background & Aims: Non-alcoholic fatty liver disease and alcohol-related liver disease pose an important challenge to current clinical healthcare pathways because of the large number of at-risk patients. Therefore, we aimed to explore the cost-effectiveness of transient elastography (TE) as a screening method to detect liver fibrosis in a primary care pathway. Methods: Cost-effectiveness analysis was performed using real-life individual patient data from 6 independent prospective cohorts (5 from Europe and 1 from Asia). A diagnostic algorithm with conditional inference trees was developed to explore the relationships between liver stiffness, socio-demographics, comorbidities, and hepati…

0301 basic medicinemedicine.medical_specialtyTransient elastographyPopulationLiver fibrosisDisease03 medical and health sciencesLiver disease0302 clinical medicineFibrosisInternal medicinemedicineeducationeducation.field_of_studyAlcohol-related liver diseaseHepatologybusiness.industryFatty liverCost-effectiveness analysismedicine.disease3. Good health030104 developmental biologyStratified screening030211 gastroenterology & hepatologyTransient elastographybusinessHepatic fibrosisNon-alcoholic fatty liver disease
researchProduct

Epidemiology ofHelicobacter pyloriinfection

2018

This review provides the most recent data concerning the epidemiology of Helicobacter pylori infection. Overall, the trend of declining prevalence of H. pylori infection is continuing, with major evidence available from studies in Europe. However, in some parts of the world, for example, in some countries in the Middle East, the prevalence has remained relatively stable. A number of systematic reviews and meta-analyses have been published during the past year indicating the lowest prevalence rates of the infection in Oceania (24.4%), the highest in Africa (79.1%), and the global annual recurrence rate of H. pylori (4.3%). The recurrence rates were found to be directly related to the human d…

0301 basic medicinemedicine.medical_specialtybusiness.industryGastroenterologyGeneral MedicineHelicobacter InfectionsEurope03 medical and health sciences030104 developmental biology0302 clinical medicineInfectious DiseasesInternal medicineNorth AmericaEpidemiologyPrevalencemedicineHumans030211 gastroenterology & hepatologybusinessBrazilHelicobacter
researchProduct

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

2021

Summary Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.

0301 basic medicinemedicine.medical_specialtyelastographyCirrhosisHepatologydecompensationbusiness.industrycirrhosisNon invasiveMEDLINENASHmedicine.diseaseClinical Practice03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicinemedicine030211 gastroenterology & hepatologyDecompensationIntensive care medicinebusinessserum markers of fibrosiscirrhosis decompensation elastography NASH serum markers of fibrosis
researchProduct

Association of Non-Invasive Markers of Liver Fibrosis with HCV Coinfection and Antiretroviral Therapy in Patients with HIV

2019

Abstract The aim of this study was to assess the main effects and interaction between viral hepatitis C (HCV) coinfection and antiretroviral therapy (ART) by using a nonparametric ANOVA on direct and indirect markers of liver fibrosis in HIV-infected patients. The sample included 178 HIV patients aged from 23 to 65 (36% females). The following parameters were determined in blood of patients: hyaluronic acid, pro-matrix metalloproteinase-1, alanine aminotransferase, aspartate aminotransferase, and platelet count. The FIB-4 index was also calculated. The nonparametric ANOVA revealed no significant interaction between HCV coinfection and ART. This provides evidence for an independent contribut…

0301 basic medicinemedicine.medical_specialtyfib-4Liver fibrosisScienceHuman immunodeficiency virus (HIV)medicine.disease_causeGastroenterologypro-mmp-103 medical and health sciences0302 clinical medicineInternal medicinehyaluronic acidmedicinePlateletliver fibrosisMultidisciplinaryaltNon invasiveQmedicine.disease030112 virologyAntiretroviral therapyCoinfection030211 gastroenterology & hepatologyAnalysis of variancenonparametric anovaViral hepatitisastProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct